Ranbaxy tackles low investor confidence and "MAC" clause concerns - update
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratorieshas been battling low investor confidence and intense speculation on the potential fallout of the US investigations on its deal with Daiichi Sankyoof Japan.